Functional foods: The case for closer evaluation

British Medical Journal

Volumn 334, Issue 7602, 2007, Pages 1037-1039

  De Jong, Nynke ^b   Verhagen, Hans ^a,b   Wolfs, Marion C J ^b   Ocké, Marga C ^b   Klungel, Olaf H ^c   Leufkens, Hubert G M ^c  

^a Centre for Nutrition and Health   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCITONIN; CORTICOSTEROID DERIVATIVE; ESTROGEN DERIVATIVE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAXATIVE; LOPERAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESALAZINE; ORAL ANTIDIABETIC AGENT; PHYTOSTEROL; RIMONABANT; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT;

ARTICLE; DRUG ACTIVITY; DRUG TARGETING; EUROPEAN UNION; FOOD DRUG INTERACTION; FOOD SAFETY; FUNCTIONAL FOOD; HUMAN; LIFESTYLE; MARKETING; NUTRITIONAL ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SAFETY;

EID: 34249323786     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39196.666377.be     Document Type: Article

References (27)

1. Pletscher W. Functional food: a growing and not clearly controlled market with a risk potential ranging from a food to a drug. Swiss Med Wkly 2004;134:367-8.
2. European Commission. Novel foods legislation. 2007 http://europa. eu.int/comm/food/food/biotechnology/novelfood/legisl_en.htm
3. Aggett PJ, Antoine JM, Asp NG, Bellisle F, Contor L, Cummings JH, et al. PASSCLAIM: consensus on criteria. Eur J Nutr 2005;44(suppl 1):i5-30.
4. European Commission. Health and nutrition claims. http://ec.europa.eu/food/food/labellingnutrition/daims/index_en.htm
5. Gilbert D, Whalley T, New B. Lifestyle medicines. BMJ 2000;321:1341-4.
6. Pariza MW. Functional foods: technology, functionality, and health benefits. Nutr Today 1999;34:3.
7. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996;313:649-51.
8. Leatherhead Food International. The international market for functional foods. Market report leaflet. June 2006. www.leatherheadfood.com/ lfi/pdf/ffoods2.pdf.
9. Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol loweringin normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 1999;53:319-27.
10. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-78.
11. Miettinen TA, Gylling H. Plant stanol and sterol esters in prevention of cardiovascular diseases. Ann Med 2004;36:126-34.
12. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995;333:1308-12.
13. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000;86:46-52.
14. Patel MD, Thompson PD. Phytosterols and vascular disease. Atherosclerosis 2006;186:12-9.
15. Ratnayake W, Vasavour E. Potential health risks associated with large intakes of plant sterols. In: Dutta PC, ed. Plant sterols: analytical, nutritional and safety aspects as functional food components. New York: Marcel Dekker, 2004:365-96.
16. Home Health Canada. Health Canada advises that Becel Pro-activ not approved for sale. Oct 2001. www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/2001/2001_106_e.html.
17. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart 2004;90:1065-6.
18. Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, Verschuren WM, Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol 2005;60:83-9.
19. Scientific Committee on Food. Opinion of the Scientific Committee on Food on a report on post launch monitoring of "yellow fat spreads with added phytosterol esters." Brussels: SCF, 2002.
20. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005;98:1-14,
21. Ohnishi N, Yokoyama T. Interactions between medicines and functional foods or dietary supplements. Keio J Med 2004;53:137-50.
22. de Jong N, Fransen HP, van den Berg SW, Ocké MC. Postlaunch monitoring of functional foods - methodology development (III), report number 350030006. Bilthoven: RIVM, 2005.
23. de Jong N, Zuur A, Wolfs MCJ, Wendel-Vos GCW, van Raaij JMA, Schuit AJ. Exposure and effectiveness of phytosterol- and stanol-enriched margarines. Eur J Clin Nutr 2007 Feb 14Epub ahead of print.
24. Wolfs M, de Jong N, Ocke MC, Verhagen H, Verschuren WMM. Effectiveness of customary use of phytosterol/-stanol enriched margarines on blood cholesterol lowering. Food Chem Toxicol 2006;44:1682-8.
25. Allgood GS, Kuter DJ, Roll KT, Taylor SL, Zorich NL. Postmarketing surveillance of new food ingredients: results from the program with the fat replacer olestra. Regul Toxicol Pharmacol 2001;33:224-33.
26. Butchko HH, Stargel WW. Aspartame: scientific evaluation in the postmarketing period. Regul Toxicol Pharmacol 2001;34:221-33.
27. Lea LJ, Hepburn PA. Safety evaluation of phytosterol-esters. Part 9: results of a European post-launch monitoring programme. Food Chem Toxicol 2006;44:1213-22.